Efficacy and Safety of SYN-010 in IBS-C

NCT03763175 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

59

Enrollment

OTHER

Sponsor class

Stopped Interim Futility Analysis

Conditions

Irritable Bowel Syndrome With Constipation

Interventions

DRUG: SYN-010 21 mg
DRUG: SYN-010 42 mg
DRUG: Placebo

Sponsor

Cedars-Sinai Medical Center

Collaborators

[object Object]